Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

[1]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[2]  M. Gleave,et al.  Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Nabhan.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer , 2015 .

[4]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[5]  Eric Bender,et al.  Challenges: Crowdsourced solutions , 2016, Nature.

[6]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Laura M. Heiser,et al.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.

[8]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[9]  Oumar Gaye,et al.  Avoiding Data Dumpsters--Toward Equitable and Useful Data Sharing. , 2016, The New England journal of medicine.

[10]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Chin-Tsang Chiang,et al.  Estimation methods for time‐dependent AUC models with survival data , 2009 .

[12]  Farid Neema,et al.  Data sharing , 1998 .

[13]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[14]  Nci Dream Community.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .

[15]  Mark Barnes,et al.  A Global, Neutral Platform for Sharing Trial Data. , 2016, The New England journal of medicine.

[16]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[17]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[18]  T. Salakoski,et al.  Regularized Machine Learning in the Genetic Prediction of Complex Traits , 2014, PLoS genetics.

[19]  Adam A. Margolin,et al.  Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer , 2013, Science Translational Medicine.

[20]  Marcia McNutt,et al.  Data sharing , 2016, Science.

[21]  M. Morris,et al.  Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J C Costello,et al.  Seeking the Wisdom of Crowds Through Challenge‐Based Competitions in Biomedical Research , 2013, Clinical pharmacology and therapeutics.

[23]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[24]  Yang Xie,et al.  A community computational challenge to predict the activity of pairs of compounds Citation , 2015 .

[25]  O. Sartor,et al.  The Changing Landscape of Metastatic Prostate Cancer , 2015 .

[26]  P. Albers,et al.  Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[28]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[29]  M. Gleave,et al.  Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Thierry Gil,et al.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.

[31]  M. Moyad.  Docetaxel and Prednisone with or without Lenalidomide in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer ( MAINSAIL ) : A Randomised , Double-Blind , Placebo-Controlled Phase 3 Trial , 2015 .

[32]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[33]  I. Tannock,et al.  A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.

[34]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[35]  Joshua M. Stuart,et al.  Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection , 2015, Nature Methods.

[36]  S. Friend,et al.  Crowdsourcing biomedical research: leveraging communities as innovation engines , 2016, Nature Reviews Genetics.